<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03216980</url>
  </required_header>
  <id_info>
    <org_study_id>HM20009929</org_study_id>
    <nct_id>NCT03216980</nct_id>
  </id_info>
  <brief_title>Examining the Effect of Mental Health Disorders on Vascular Function and Exercise Tolerance</brief_title>
  <official_title>Examining the Effect of Mental Health Disorders on Vascular Function and Exercise Tolerance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Specific Aim #1: Examining the impact of mental health disorders (PTSD and GAD) on peripheral&#xD;
      vascular function and sympathetic nervous system activity in young individuals.&#xD;
&#xD;
      Specific Aim #2: Examining the impact of mental health disorders (PTSD and GAD) on peripheral&#xD;
      hemodynamics and metabolic byproducts during small muscle mass exercise in young individuals.&#xD;
&#xD;
      Specific Aim #3: Examining the impact of mental health disorders (PTSD and GAD) on exercise&#xD;
      tolerance, peripheral hemodynamics and metabolic byproducts during large muscle mass exercise&#xD;
      in young individuals.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mental health disorders are highly prevalent and underdiagnosed and can cause perturbations&#xD;
      in cardiovascular and metabolic function leading to substantial individual burden (increased&#xD;
      health care cost, loss of work productivity). Post-traumatic stress disorder (PTSD) and&#xD;
      generalized anxiety disorder (GAD), two common mental health disorders, can cause increase&#xD;
      cardiovascular disease risk due to chronic increases or fluctuations in heart rate, blood&#xD;
      pressure, stress hormones, inflammation, and oxidative stress. Post-traumatic stress disorder&#xD;
      (PTSD) is a disabling psychiatric condition characterized by a persistent maladaptive&#xD;
      reaction resulting from exposure to severe psychological stress. It has been revealed that&#xD;
      individuals with PTSD, in addition to adverse mental health symptoms, also possess higher&#xD;
      prevalence rates for physical comorbidities such as hypertension, obesity, diabetes, and&#xD;
      metabolic syndrome. Taken together, these PTSD-induced comorbidities result in a significant&#xD;
      increase in the likelihood of developing cardiovascular disease (CVD) when compared to&#xD;
      individuals without PTSD. Anxiety disorders, the most prevalent mental health issue in the&#xD;
      United States, is associated an increased incidence of hypertension and heart disease. This&#xD;
      increased cardiovascular disease (CVD) risk is thought to derive from an overactivation of&#xD;
      the sympathetic nervous system that results in a predominately pro-oxidant, pro-inflammatory&#xD;
      cardiovascular environment. Peripheral vascular dysfunction, or the inability of the blood&#xD;
      vessels to adequately respond to specific stimuli, is a factor closely related to CVD.&#xD;
      Therefore, this study will focus on a younger population with PTSD or GAD in an attempt to&#xD;
      ascertain the presence of peripheral vascular dysfunction and the magnitude to which two&#xD;
      potential primary contributors (autonomic dysfunction, oxidative stress) are involved in this&#xD;
      dysfunction.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 15, 2017</start_date>
  <completion_date type="Actual">March 31, 2021</completion_date>
  <primary_completion_date type="Actual">March 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arm Vascular Function at Rest (Flow Mediated Dilation Test) and in Response to Exercise (Handgrip Exercise Test)</measure>
    <time_frame>Before and Immediately After Intervention</time_frame>
    <description>Change in Brachial Artery Dilation from Baseline Values</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Leg Vascular Function (Passive Leg Movement Test)</measure>
    <time_frame>Before and Immediately After Intervention</time_frame>
    <description>Change in Leg Blood Flow Values from Baseline</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Mental Health Disorders</condition>
  <arm_group>
    <arm_group_label>PTSD/GAD Antioxidant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PTSD/GAD Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will ingest placebo (microcrystalline cellulose) pills.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control Antioxidant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will ingest placebo (microcrystalline cellulose) pills.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>PTSD/GAD Antioxidant</intervention_name>
    <description>Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).</description>
    <arm_group_label>PTSD/GAD Antioxidant</arm_group_label>
    <arm_group_label>PTSD/GAD Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>PTSD/GAD Placebo</intervention_name>
    <description>Subjects will ingest placebo (microcrystalline cellulose) pills.</description>
    <arm_group_label>PTSD/GAD Antioxidant</arm_group_label>
    <arm_group_label>PTSD/GAD Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Healthy Control Antioxidant</intervention_name>
    <description>Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).</description>
    <arm_group_label>Healthy Control Antioxidant</arm_group_label>
    <arm_group_label>Healthy Control Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Healthy Control Placebo</intervention_name>
    <description>Subjects will ingest placebo (microcrystalline cellulose) pills.</description>
    <arm_group_label>Healthy Control Antioxidant</arm_group_label>
    <arm_group_label>Healthy Control Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  apparently healthy and free of overt cardiovascular, pulmonary, or metabolic disease&#xD;
&#xD;
          -  for PTSD group, a score of ≥ 33 on PCL-5 checklist&#xD;
&#xD;
          -  for GAD group, a score of ≥ 10 on the GAD-7 self-report scale&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  taking medications that could influence cardiovascular function&#xD;
&#xD;
          -  limited English proficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryan Garten, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 27, 2017</study_first_submitted>
  <study_first_submitted_qc>July 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2017</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cardiovascular disease</keyword>
  <keyword>vascular function</keyword>
  <keyword>PTSD</keyword>
  <keyword>GAD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antioxidants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

